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Background: In the direct pathway, T cells recognize intact donor major histocompatability complexes and
allogeneic peptide on the surface of donor antigen presenting cells (APCs). Indirect allorecognition results from the
recognition of processed alloantigen by self MHC complexes on self APCs. In this study, we wished to evaluate the
relative contribution of different intragraft cells to the alloactivation of naïve and memory T cells though the direct
and the indirect pathway of allorecognition.
Methods: The processing of membrane fragments from IFNγ-treated single donor endothelial cells (EC), fibroblasts
or renal epithelial cells (RPTEC) was evaluated by DiOC labeling of each cell type and flow cytometry following
interaction with PBMC. Direct pathway activation of naïve CD45RA+ or memory CD45RO+ CD4+ T cells was
evaluated following coculture with IFNγ-treated and MHC class II-expressing EC, fibroblasts or RPTEC. Indirect
pathway activation was assessed using CD45RA+ or CD45RO+ CD4+ T cells cocultured with autologous irradiated
APCs in the absence or presence of sonicates derived from IFNγ-treated allogeneic EC, fibroblasts or RPTEC.
Activation of T cells was assessed by [3 H]thymidine incorporation and by ELISpot assays.
Results: We find that CD14+ APCs readily acquire membrane fragments from fibroblasts and RPTEC, but fail to
acquire membrane fragments from intact EC. However, APCs process membranes from EC undergoing apoptosis.
There was a notable direct pathway alloproliferative response of CD45RO+ CD4+ T cells to IFNγ-treated EC, but not
to fibroblasts or RPTEC. Also, there was a minimal direct pathway response of CD45RA+ CD4+ T cells to all cell types.
In contrast, we found that both CD45RA+ and CD45RO+ CD4+ T cells proliferated following coculture with
autologous APCs in the presence of sonicates derived from IFNγ-treated EC, fibroblasts or RPTEC. By ELISpot, we
found that these T cells stimulated via the indirect pathway also produced the cytokines IFNγ, IL-2, IL-4 and IL-5.
Conclusions: Recipient APCs may readily process membrane fragments from allogeneic intragraft cells, but not
from EC unless they are undergoing apoptosis. This processing is sufficient for indirect pathway alloactivation of
both CD45RA+ and CD45RO+ CD4+ T cells. Only graft vascular EC mediate direct pathway reactivation of CD4+ T
cells.
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Recipient CD4+ T cell recognition of alloantigen is the cen-
tral and primary event that ultimately leads to the initi-
ation of allograft rejection [1-3]. It is now well established
that alloactivation of T cells occurs via two distinct
pathways [4-10]. In the direct pathway of allorecogni-
tion, CD4+ T cells recognize intact allogeneic major
histocompatibility complex (MHC) antigens expressed
on the surface of donor cells. In the indirect pathway of
allorecognition, CD4+ T cells recognize allogeneic pep-
tides processed and presented by self-MHC molecules
on the surface of recipient antigen presenting cells
(APCs). While the central determinant of allorespon-
siveness is recognition of alloantigen, it has become evi-
dent that both pathways can contribute to the
development of acute and chronic rejection and/or on-
going injury to the graft [7,11,12].
In traditional immunological models, it is suggested
that both naïve and memory CD4+ T cells contribute to
rejection through the direct pathway, whereas indirect
pathway allorecognition is dominantly associated with
activation of the naïve repertoire of T cells [7,10,13,14].
This model is based on the hypothesis that the memory
T cell repertoire results from expanded populations of
T cells that have responded to previous antigen encoun-
ters. In contrast, activation of naïve populations of T cells
is continuous and results from ongoing APC-dependent
presentation of alloantigen via both direct and indirect
pathways [13]. Since, naïve T cells are largely made up of
single cells with different specificities, this indicates that
the allogeneic response(s) can be very diverse. In addition,
it is well known that the precursor frequency of T cells
with direct allospecificity is high [4,15]. This suggests that
the memory subset alone is unlikely to account for the
direct allorecognition response. While the frequency
of T cells with indirect specificity is low, they are
well established to increase over time following
transplantation [16-18]. Thus, it is likely that the
continuous activation of naïve T cells via indirect
presentation of alloantigen by self-APCs will be dom-
inant for the generation of persistent allogeneic
responses.
The vascular endothelium functions in the recruitment
of recipient immune competent cells into the graft [19-
21]. Donor graft vascular endothelial cells (EC) also ex-
press MHC class I and II molecules, and have been
reported to be potent to provide costimulation for the ef-
fective alloactivation of human T cells [20,22-24]. In
addition, following re-endothelialization of donor grafts,
recipient EC lining vessels within the graft have been
found to be efficient in the activation of T cells in a self-
restricted manner via the indirect pathway of alloactiva-
tion [25,26]. Since both acute and chronic rejection
requires interactions among T cells and graft vascularEC, it is proposed that this cell type may serve as a
primary candidate to foster the reactivation of T cells,
and perhaps the modification of activation responses
via both direct and indirect allorecognition [8,25-27].
However, some reports have suggested that endothelial
cells lack the ability to provide effective costimulation
to T cells [28,29], and others suggest that the expres-
sion of MHC class II expression by endothelial cells is
not necessary for the rejection response [30]. Neverthe-
less, these observations do not exclude the importance
of donor EC in the promotion of indirect allorecogni-
tion via interactions with APCs [23], and their effect in
this latter response is poorly understood.
Few studies have evaluated the ability of interstitial
intragraft cells to facilitate direct and indirect allore-
cognition. The lack of expression of costimulatory
molecules by fibroblasts and renal tubular epithelial
cells (RPTEC) limits their ability to induce T cell activa-
tion [31-34]. In this report, we used well-established
in vitro models to compare the effect of EC, fibroblasts
and RPTEC in direct and indirect alloactivation of naïve
CD45RA+ and memory CD45RO+ CD4+ T cells. Our
findings indicate that EC, but not fibroblasts or RPTEC,
provide direct pathway allorecognition to CD45RO+
memory subsets of CD4+ T cells. In addition, we find that
all cell types facilitate indirect allorecognition to both
CD45RA+ naïve and CD45RO+ memory CD4+ T cell
subsets.
Methods
Cell Isolation and Culture
Single donor endothelial cells (EC) were isolated from
human umbilical cords as previously described [35], and
were grown in M199 medium (Bio Whittaker) containing
20% FCS (GIBCO BRL, Grand Island NY) or 10% human
serum, EC growth supplement, 1% penicillin/streptomycin,
l-glutamine, and heparin. Single donor fibroblasts and
renal tubular epithelial cells (RPTEC) were purchased from
Clonetics and cultured in CC-4126 FGM 2 or CC-4127
REGM (Clonetics, Walkersville MD) according to the
manufacturer’s protocol. EC, fibroblasts and RPTEC were
treated with IFNγ (1000U/ml, R&D Systems, Minneapolis,
MN) for 72 h prior to use. EC were used in subculture
3–4. Apoptosis was induced in EC monolayers following
treatment with TNF-α (200 U/ml, Biogen, Cambridge
MA) and cyclohexamide (2 ng/ml, Sigma, St. Louis, MO)
for 7 h. Peripheral blood mononuclear cells (PBMC) were
isolated by Ficoll-Hypaque gradient centrifugation from
healthy volunteers. CD4+ T cells were isolated from
PBMC by positive selection using anti-CD4-coated mag-
netic beads (Invitrogen, Grand Island NY) according to
the manufacturer’s protocol. CD4+CD45RA+ and CD4+
CD45RO+ cells were isolated from CD4+ cells by negative
selection using magnetic beads coated with mouse anti-
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Grand Island NY).
Lymphocyte transmigration assays
Transmigration experiments were conducted using EC,
fibroblasts or RPTEC monolayers cultured on fibronectin
(50 μg/ml) coated 3μm pore size transwell inserts (Costar,
Cambridge, MA, USA) as previously described [35,36]. A
total of 3×103 EC, fibroblasts or RPTEC were seeded onto
inserts and were allowed to grow for 4–5 days. Monolayers
were treated with IFNγ (1000U/ml, R&D systems) for the
last 72 culture. Confluence of the monolayers was con-
firmed by Coomasie staining using standard techniques
[37]. Monolayers were labeled with DiOC-16 (5 μg/ml,
Molecular Probes, Eugene OR, USA), which incorporates
into the membranes of cells and has an emission at
501 nm. A total of 1x106 PBMC were placed into the upper
transwell and cells were collected from the bottom well
after 1.5h. Following collection, DiOC uptake was analyzed
on CD14+ CD4+ and CD8+ cells by flow cytometry.
Flow cytometry
Confluent monolayers were harvested in Trypsin/EDTA
(Sigma, St. Louis, MO) and were analyzed by indirect
immunofluorescence staining and flow cytometry as
previously described [23]. Briefly, cells were incubated
in optimal concentrations of the primary antibodies
anti-HLA DR (LB3.1, ATCC, Manassas, VA), negative
control mouse IgG (K16/16, a gift from Michael Gimbrone,
Brigham and Women’s Hospital) or positive control anti-
ICAM-1 (RR1/1, a gift from TS Springer) for 30 mins on
ice. Cells were washed and subsequently incubated in
FITC-conjugated anti-mouse secondary antibody (Jackson,
Immunoresearch, West Grove, PA) for an additional
30 mins on ice, and stained cells were washed and fixed
in 1% paraformaldehyde prior to analysis. Leukocytes
were stained using Phycoerythrin (PE) conjugated anti-
human -CD14, -CD4 and -CD8 antibodies (PharMingen,
San Diego CA) or isotype negative controls using stand-
ard techniques. All stained cells were analyzed using a
FACSCalibur cell sorter (Becton Dickinson, Mountain
View, CA) and CellQuest and FlowJo software.
PBMC-allogeneic cell coculture
EC, fibroblasts or RPTEC were cultured to confluence
in fibronectin-coated 24-well flat-bottom plates (Costar)
coated with fibronectin (50 μg/ml) and treated with IFNγ
(1000U/ml) for 72 h. PBMC (1x106/well) were added and
were cultured for 7 days in standard RPMI 1640 medium
containing 10% autologous serum. Subsequently, PBMC
were harvested by washing with HBSS and CD4+ T cells
were isolated by positive selection (Invitrogen, Grand
Island NY) and were rested in culture medium contain-
ing 2.5% of human T-stim without PHA (Becton DickinsonLabware, Bedford, MA) for 5 days. The allogeneic HLA
mismatch between PBMCs and stimulator EC, fibro-
blasts or RPTEC was unknown, but was presumed based
on consistency of the response in multiple repeated
experiments.
Preparation of Sonicates
Cell membranes were prepared as sonicates from IFN-γ
treated EC, fibroblasts and RPTEC. Exactly 8 × 106 of
each cell type was washed and suspended in 1 ml of ster-
ile PBS and was sonicated using a tip sonicator (Branson
Sonifer 250) fitted with a 2 mm probe. Disrupted cells
were centrifuged for 10 min at 500 g to remove debris. A
total of 20μl of sonicate was used in each assay. As a
quality control, the protein content per ml was measured
in occasional sonicate supernatants by standard Bradford
assay. Sonicates were frozen at −20°C and thawed at 37°C
before use.
Indirect allorecognition assays
CD4+ T cells (1x105/well) isolated from primary cultures
(above) were used with autologous APCs in proliferation
assays. Autologous APCs (1x105/well) were isolated from
Tcell-depleted PBMC, were irradiated (1750 rad) and used
as stimulators. Assays were performed in round-bottom
96-well plates (Costar). Sonicates from the allogeneic cells,
were added (as above) to each culture and, after 6 days
proliferation was assessed by standard [3H]thymidine in-
corporation assays (1μCi/well) for the last 16 h of the
coculture.ELISPOT assays
ELISpot was performed in 96-well plates (Cellular Tech-
nology Ltd., Cleveland, OH) coated overnight with cap-
ture cytokine antibodies diluted in sterile PBS.
Antibodies were mouse anti-human IFNγ (clone 2 G1,
Endogen, Wolburn, MA, 4μg/ml), mouse anti-human
IL-2 (clone 5355, R&D Systems Inc., Minneapolis, MN,
5μg/ml), mouse anti-human IL-4 (clone 8D4-8, BD
PharMingen, San Diego, CA, 5μg/ml) or rat anti-human
IL-5 (clone TRFK5, PharMingen, San Diego, CA, 5 μg/ml).
After blocking for 1 h with PBS/1%BSA, the plates were
washed and CD4+ T cells (2x105/well) were cultured with
autologous APCs (2x105/well) in the absence or presence
of sonicate. The plates were incubated at 37°C in 5% CO2
for 24-36 h. Detection antibodies were biotinylated mouse
anti-human IFN-γ (clone B133.5, Endogen, 2μg/ml), mouse
anti-human IL-2 (clone 5334, R&D Systems Inc., 50 ng/ml),
rat anti-human IL-4 (clone MP4-25D2, BD PharMingen,
2μg/ml) and rat anti-human IL-5 (clone JES1-5A10, Phar-
Mingen, 2μg/ml). After overnight incubation at 4°C, the
plates were washed and cytokines were detected using
streptavidin HRP (Daco, Carpenteria, CA) and 3-amino-9-
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were counted using a computer-assisted ELISpot image
analyzer (Cellular Technologies Limited).Statistical analyses
Statistical analysis was performed using the student t test
for two groups of data and by one-way ANOVA for three
or more groups. P values <0.05 were considered statistically
significant.Figure 1 Transfer of the dye from EC, fibroblasts or RPTEC to CD14+ m
fibroblasts and RPTEC were grown on transwell inserts and labeled with th
before each experiment. A total of 1x106 PBMC were placed into the uppe
lower chamber and were collected after 1.5 h. Panel A, DiOC uptake was as
cells following transmigration. Panel B, Uptake of DiOC was assessed on CD
Apoptosis was induced in EC by TNF-α and cyclohexamide treatment. The
each panel. Results are representative of ≥10 experiments for each cell typeResults
CD14+ monocytes acquire membrane fragments from
fibroblasts and RPTEC, but not EC
We initially evaluated whether APCs acquire membrane
fragments from allogeneic cells during brief interactions in
the course of transmigration. We used a standard trans-
well model in which PBMC were allowed to transmigrate
through confluent IFNγ-treated EC, fibroblasts or RPTEC.
Prior to the assay, cells were labeled with lipophylic DiOC-
16, which is well established to stably incorporate into cellonocytes in transmigration assays. Confluent monolayers of EC,
e lipophylic dye, DiOC-16. Labeled cells were washed extensively
r chamber of the transwell, were allowed to transmigrate into the
sessed by FACS analysis on CD14+ monocytes and on CD4+ or CD8+ T
14+ monocytes following interactions with EC undergoing apoptosis.
percent double positive cells is shown in the right upper corner of
, and was identical when different PBMCs and cell lines were used.
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65% of CD14+ monocytes acquired dye after interaction
with both fibroblasts and RPTEC. However, surprisingly,
the transfer of dye was very limited after interaction with
EC. We also found that neither CD4+ T cells nor CD8+ T
cells acquire dye from any allogeneic cell type indicating
that the transfer was related to phagocytosis of membrane
rather than through cell surface membrane transfer (as can
occur in the semi-direct pathway of allorecognition [7,38]).
To further confirm that intact EC fail to transfer membrane
to APCs, we also assessed transfer when PBMC transmi-
grated across EC undergoing apoptosis (TNFα- and cyclo-
hexamide- treated cells). As illustrated in Figure 1B, we
find that APCs acquire DiOC-labeled membrane from
apoptotic EC (15-25% cells) as compared to untreated or
IFNγ-treated EC (3-10% cells). In contrast, the transmigra-
tion of PBMC across apoptotic fibroblasts or RPTEC did
not alter DiOC-labeled membrane uptake from that
described above (data not shown). Therefore, it is possible
that acute injury or alloimmune targeting of EC may be a
factor in the initiation of indirect processing of alloantigen
by APCs. This process may result in crosstalk between
both pathways of allorecognition, as described [8].
Direct and indirect allorecognition by CD45RA+ and
CD45RO+ CD4+ T cells in response to IFNγ-treated EC,
fibroblasts or RPTEC
We next wished to compare the ability of EC, fibroblasts
and RPTEC to induce direct and indirect pathway alloacti-
vation of naïve CD45RA+ and memory CD45RO+ CD4+ T
cells. CD45RA+ and CD45RO+ cells were isolated by nega-
tive selection from pure populations of CD4+ T cells
(>90% purity by FACS, data not shown) and were cocul-
tured with IFNγ-treated EC, fibroblasts or RPTEC for
5 days. As illustrated in Figure 2A, and consistent with
other reports [23,39,40], we find that our IFNγ-treated EC,
fibroblasts and RPTEC express high levels of MHC class II.
However, CD45RO+CD4+ T cells showed significant
proliferation only in response to culture with allogen-
eic EC, and had minimal proliferative responses when
cultured with fibroblasts or RPTEC (Figure 2B). In
contrast, there was a minimal proliferative response of
CD45RA+CD4+ T cells to all allogeneic stimulator cell
types (Figure 2B). This observation is consistent with
previously published reports indicating that EC func-
tion in the activation of allogeneic T cells [22,23,41,42].
They are also consistent with previous studies indicating
that EC fail to provide sufficient costimulation for the
initiation of naïve T cell activation responses [23,28].
In order to evaluate the effect of each cell type in indir-
ect alloactivation, we next cocultured CD45RA+ or
CD45RO+ CD4+ T cells with autologous APCs in the ab-
sence or presence of sonicate derived from allogeneic 72 h
IFNγ-treated EC, fibroblasts and RPTEC (as shown inFigure 2A). In these assays, T cells cultured in the presence
of autologous APCs without sonicate served as a negative
control. Illustrated in Figure 3A, we find that both naïve
CD45RA+ as well as memory CD45RO+ CD4+ T cells pro-
liferate to sonicates prepared from all cell types. As a con-
trol, each T cell subset failed to proliferate to sonicate alone
in the absence of autologous APCs (Figure 3B). These
observations indicate that indirect allorecognition is a most
potent mechanism for the allogeneic activation of both
naïve and memory T cells.
Effect of sensitization on indirect allorecognition by CD4+
T cells
We next created an in vitro model to evaluate whether
there is a difference in indirect responses among unsen-
sitized and sensitized CD4+ T cells. For this purpose, we
cultured PBMC with IFNγ-treated EC, fibroblasts or
RPTEC. After 7 days, the CD4+ T cells were isolated from
the cultures and were rested in culture medium alone.
After 5 days of rest, these sensitized T cells (or freshly iso-
lated unsensitized cells) were then used as responders in
cocultures with autologous APCs in the absence or pres-
ence of sonicates derived from the allogeneic EC, fibro-
blast or RPTEC used in the primary culture. Proliferation
was again assessed on day 6. Illustrated in Figure 4, we
found no difference in the proliferative responses of
unsensitized or sensitized T cells in these indirect allore-
cognition assays. By ELISpot (48 h), we found variations in
individual cytokine production between sensitized and
unsensitized cells (Figure 4B). However, the overall pro-
duction of cytokines was at high levels reflective of the ac-
tivation status of the T cells and there were no significant
differences between responses in unsensitized and sensi-
tized cells (data not shown). ELISpot counts for IFNγ were
generally higher when EC were used as the alloantigen, as
compared to assays where fibroblasts and RPTEC were
used (Figure 4B). Collectively, these observations further
confirm that the indirect response is potent to initiate T
cell activation, and indicate that T cells primed through
the indirect pathway may be reactivated within allografts
upon encounter with self-APCs.
Discussion
In the current study, we find that MHC class II-expressing
EC are potent for direct pathway allogeneic reactivation
of memory T cell subsets, and that direct pathway activa-
tion does not occur following interactions with fibroblasts
or renal tubular epithelial cells. In addition, we find that
CD14+ monocyte/APCs readily acquire membrane parti-
cles from fibroblasts as well as renal epithelial cells and
that this process is sufficient to induce indirect pathway
allogeneic activation of both naïve and memory T cells. In
contrast, the ability of monocytes to phagocytose mem-
brane particles from intact EC is limited, and acquisition
Figure 2 Direct alloactivation of naive and memory T cells by IFNγ-treated EC, fibroblasts and RPTEC. Panel A, FACS analysis of MHC class
II on EC, fibroblasts and RPTEC, either untreated or following treatment with IFNγ for 48 and 72 h, as indicated, using mouse anti-human HLA-DR
(LB3.1, solid black lines) or negative control mouse IgG (K16/16, grey lines). The expression of ICAM-1 served as a positive control (not shown).
Panel B, Naïve CD45RA+ and memory CD45RO+ CD4+ T cells were isolated from PBMC. A total of 1x105 CD45RA+CD4+ T cells (white bars) or
CD45RO+CD4+ T cells (black bars) were cocultured either alone (striped bars) or with 5x104 allogeneic IFNγ-treated EC, fibroblasts or RPTEC (solid
bars) for 5 days. Proliferation was assessed by [3 H] thymidine incorporation. Results are representative of at least 3 experiments performed in
triplicate ± 1SD (*P< 0.05) using cells from different donors and responders.
Samsonov et al. Transplantation Research 2012, 1:4 Page 6 of 10
http://www.transplantationresearch.com/content/1/1/4
Figure 3 Indirect alloactivation of naive and memory T cells following coculture with autologous APCs in the presence of sonicates
derived from allogeneic EC, fibroblasts or RPTEC. Naïve CD45RA+ cells and memory CD45RO+ CD4+ T cells were isolated from PBMC as
described in Methods. Panel A, 1x105 CD45RA+CD4+ T cells (white bars) or CD45RO+CD4+ T cells (black bars) were cocultured for 6 days with
1x105 irradiated autologous PBMC either alone (striped bars) or in the presence of sonicate (solid bars) prepared from allogeneic IFNγ treated EC,
fibroblasts or RPTEC. Proliferation was assessed by [3 H] thymidine incorporation. Results are representative of 3 different experiments performed in
triplicate ± 1SD (*P< 0.05). Panel B, 1x105 CD45RA+ (Upper Panel) or CD45RO+ (Lower Panel) CD4+ T cells were cultured for 6 days either alone
(gray bars) or with sonicate prepared from allogeneic IFNγ-treated EC (black bars), fibroblasts (striped bars) or RPTEC (checked bars). Proliferation
was assessed by [3 H] thymidine incorporation. The illustrated results in Panels A and B are representative of 3 different experiments performed in
triplicate ± 1SD.
Samsonov et al. Transplantation Research 2012, 1:4 Page 7 of 10
http://www.transplantationresearch.com/content/1/1/4by APCs requires apoptosis of EC. Nevertheless, once
APCs process particulates from allogeneic EC, these APCs
are most potent to induce indirect alloactivation of T cell
subsets. These observations are consistent with the hy-
pothesis that memory CD4+ T cells contribute to rejectionthrough direct pathway interactions with allogeneic EC. In
addition, they indicate that indirect pathway allorecogni-
tion can occur following processing of alloantigen by all
cell types, and this pathway is dominant for the activation
of naïve repertoires of human T cells.
Figure 4 Indirect alloactivation of unsensitized and sensitized CD4+ T cells by autologous APCs in the presence of sonicates derived
from allogeneic EC, fibroblasts or RPTEC. PBMC were cultured either alone on plastic or with confluent monolayers of IFNγ-treated EC,
fibroblasts or RPTEC for 7 days. Subsequently, CD4+ T cells were isolated from cultures by positive selection and, after a 5 day rest period, were
used as responders with irradiated autologous APCs in the presence of sonicate. Sonicate was derived from IFNγ-treated EC, fibroblasts or RPTEC,
as indicated, and the identical stimulator cell was used in primary and secondary cultures. Panel A, proliferation of unsensitized (white bars) and
sensitized (black bars) CD4+ T cells as assessed by [3 H] thymidine incorporation for the last 18 h of a 6 day culture. Results are representative of at
least 3 different experiments performed in triplicate ± 1SD using different donors of PBMC and different EC, fibroblasts and RPTEC. Panel B,
representative ELISpot analysis of IFNγ, IL-4, IL-2 and IL-5 following 48 h culture of unsensitized or sensitized CD4+ T cells with sonicate derived
from allogeneic EC. The results are representative of 3 different experiments. Similar cytokine production was found following indirect alloactivation of T
cells by fibroblasts and RPTEC, but the response in general was less pronounced than that found in using EC sonicates (not shown).
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described based on the observation that passenger
leukocyte-depleted renal allografts were rejected at a slower
pace than APC replete allografts [43]. It is suggested that re-
cipient APCs traffic through the graft, take up and process
soluble MHC alloantigens, as well as dead or necrotic donor
cells. After migrating back to lymph nodes these APCs
process and present alloantigens as peptides on self MHC
class II molecules to naïve CD4+ T cells [9,10]. Consistent
with this model, our in vitro studies indicate that human
naïve and memory T cells respond to autologous APCs that
have processed membrane particulates from allogeneic cells.
In addition, previous studies have confirmed that donor
MHC peptides are presented to recipient T cells through
the indirect pathway [44,45], and that these responses occur
in patients with chronic allograft rejection [11,16,17]. In-
deed, in vivo studies have confirmed that MHC-derived
antigens from allografts are commonly processed and can
initiate T effector responses [7,8,10,13,46,47].
During rejection, endothelial cells function to elicit the
recruitment of monocyte/APCs as well as activated T cells
into the graft [19,20]. Multiple studies by our own group,
as well as others, have determined that this process and
interactions with allogeneic EC may facilitate Th1 [22,48],Th2 [21,49], or Th17 [50] activation as an integral compo-
nent of the inflammatory response. Our studies high-
lighted in this report further confirm these findings, and
indicate that this response typically results from EC-
dependent reactivation of the CD45RO+ memory T cell
subset. In contrast, our observations indicate that intersti-
tial cells are ineffective for direct pathway alloactivation
of T cells. These findings are consistent with several other
reports [31-34,51] suggesting that fibroblasts and epithe-
lial cells have a limited ability to provide costimulation to
T cells. However, our new findings in this report indicate
that once APCs process membrane fragments from inter-
stitial cells, they are most potent to initiate indirect path-
way alloactivation. These findings lead to the interpretation
that antigens derived interstitial cell types are dominant to
induce indirect pathway alloactivation.
An intriguing possibility is that the processing of alloanti-
gen derived from interstitial cell types precedes subsequent
emergence of APCs from the graft and their differentiation
and maturation into mature APCs/dendritic cells. Indeed,
several studies have confirmed that processing is a pre-
requisite for dentritic cell maturation [52]. Thus, another
interpretation of our findings is that the inhibition of the
recruitment of monocytes into an allograft or the inhibition
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naïve T cell activation/indirect allorecognition.
A limitation of this study is that there is individual
variation in precursor frequencies of alloreactive memory
T cells. In the ideal experiment, one might control for
precursor cells, and each cell type should be tested
against one specific alloantigen that represents a single
MHC-derived peptide. Another limitation is that the
maturation and differentiation of APCs into mature
dendritic cells and their subsequent interaction with
naïve and memory T cells requires specific inflamma-
tory mediators and perhaps the local lymphoid micro-
environment. Nevertheless, our findings indicate that
endothelial cells are potent to induce alloresponses
through both the direct and the indirect pathway. In
contrast, fibroblasts and RPTEC selectively activate T
cells through the indirect pathway.Conclusions
Overall, these in vitro studies clearly demonstrate that
different interstitial cell types have potential to activate
allogeneic T cells either through the direct or the indirect
pathway of allorecognition. Our studies indicate that
memory T cells are reactivated upon encounter with
graft vascular EC, and that interstitial cells are weak or
inefficient to elicit direct pathway reactivation of this
subset. In contrast, we find that the indirect pathway is
potent to induce the alloactivation of both naïve and
memory T cells, and that indirect responses likely occur
as a result of APC processing of interstitial cells. Once
self-APCs migrate into allografts and have interacted
with intragraft cells, their subsequent encounter with T
cells (within an allograft or within a lymph node) has po-
tential to mediate indirect alloactivation.
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